PHOENIX, April 23, 2019 (GLOBE NEWSWIRE) -- Item
9 Labs Corp. (INLB) (âItem 9 Labsâ or
the âCompanyâ), a leader in comfortable cannabis health solutions
for the modern consumer, today released the following welcome
letter to Item 9 shareholders from Sara Gullickson, CEO.
Dear Item 9 Labs Shareholders,
As we enter Q2, I am taking this opportunity to
introduce myself as the new Chief Executive Officer of Item 9 Labs
Corp. This appointment is the culmination of many personal goals,
and a position where Item 9 Labs shareholders will benefit from the
skills and expertise gained throughout my nine-year cannabis
This industry is an ever-evolving landscape, a
fast-paced environment not for the faint of heart. Early on, it
presented a challenging opportunity and a place where I had the
potential to make history. My entrepreneurial journey began by
winning multiple medical marijuana licenses across more than a
dozen state markets, as well as helping to develop regulatory
frameworks in the United States, Canada, Europe, and New Zealand.
From the beginning I have been a pioneer, building this industry
from the ground up. Over the years, I have worked with
entrepreneurs from across the country to secure and launch their
businesses with a common goal of bringing alternative health
solutions to their communities. My experiences have been valuable
and rewarding, providing the platform needed to become a key player
in the mainstream cannabis conversation.
Research has also played a pivotal role in my
business success. I have spent a significant amount of energy in
helping to identify future market trends and building synergistic
teams which provides me with an invaluable edge over the
competition. My company has received multiple offers to be
acquired, merge or go public over the years, none of which fit
until the opportunity to merge with Item 9 Labs arose. The decision
was easy and natural as I found we had a shared mission, vision,
and ethics, which are THE key ingredients for success in the
cannabis space. As history reflects, the groups who do not stand
for something primarily end up with nothing. As part of your
leadership team, I will uphold our company ideals, valuing strategy
over a ârace to the top mentality.â
I foresee a vibrant future for Item 9 Labs, and with that horizon
in mind, I would like to share our corporate plans for 2019.
The Dispensary Permits team, now an Item 9 Labs
asset, will oversee license application filings and facility
acquisitions. This balance of opportunities will maximize our goals
to be cash flow positive since those defined as âapplicationâ will
be pre-revenue and the opportunities defined as âacquisitionâ will
be existing facilities that are revenue generating.
I look forward to connecting with all of you in the near future. To
stay updated on Item 9 Labs' journey and shareholder news,
subscribe to our newsletter -
Chief Executive Officer
Item 9 Labs Corp
Gullickson formerly served as CEO and Founder of
Dispensary Permits, which was acquired by Item 9 Labs in November
2018. Named to Marijuana Business Magazineâs 2019 Women to Watch
list, Gullickson has headlined cannabis tracks at the Real Estate
Wealth Expos in Los Angeles and Toronto, as well as other
large-scale business events. She turned down multiple offers
before developing a partnership with Item 9 Labs.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (INLB)
creates comfortable cannabis health solutions for the modern
consumer. The Company is bringing best of industry practices to
markets from coast to coast through cultivation and production,
distinctive retail environments, licensing services, and diverse
product suites catering to different medical cannabis demographics.
Item 9 Labs Corp. is headquartered in Phoenix, Arizona, with
medical cannabis operations in multiple U.S. markets.
Item 9 Labs Corp.âs asset portfolio includes
Dispensary Permits, Dispensary Templates, and Strive Life. These
assets provide services specific to different stakeholder groups.
Dispensary Permits is the Companyâs consulting firm specializing in
strategic license application and compliance. Dispensary Templates,
a subdivision of the firm, is a technology platform with an
extensive digital library of licensing and business planning
resources. Strive Life is a turnkey dispensary model for the retail
sector, elevating the patient experience with consistent and
superior service, high-end design, and precision-tested products.
It is currently being implemented in Arizona and North Dakota.
In addition, Item 9 Labs Corp. is advancing the
industry with its dynamic product suites. The Company has created
complementary brands Item 9 Labs and Strive Wellness to channel
consumer diversity. Propriety delivery platforms include the Apollo
Vape and Pod system, as well as a pioneering intra-nasal device.
The Company has received multiple accolades for its medical-grade
flower and concentrates.
Item 9 Labs Corp. will be managing cultivation,
processing, distribution, and dispensary operations in up to ten
U.S. markets by the end of 2019. Current facilities include
distribution and processing operations Strive Wellness of Ohio and
Strive Wellness of Nevada, as well as dispensary Strive Life North
For more information, visit Item 9 Labs Corp.
Statement: This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements involve risks and uncertainties, including, but not
limited to, risks and effects of legal and administrative
proceedings and governmental regulation, especially in a foreign
country, future financial and operational results, competition,
general economic conditions, proposed transactions that are not
legally binding obligations of the company and the ability to
manage and continue growth. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual outcomes may vary materially from those
indicated. Important factors that could cause actual results to
differ materially from the forward-looking statements we make in
this news release include the introduction of new technology,
market conditions and those set forth in reports or documents we
file from time to time with the SEC. We undertake no obligation to
revise or update such statements to reflect current events or
circumstances after the date hereof or to reflect the occurrence of
Item 9 Labs Corp.